"Microdosing" has become a popular term for taking a GLP-1 medication such as semaglutide or tirzepatide at a lower dose than the doses used in the major weight-loss trials. Interest in the approach comes mostly from people who want to avoid side effects or who want a more gradual experience. This article explains what the term means, what published research shows about lower doses and what that research has not established.
Important: Lower-dose GLP-1 therapy is not the treatment that was studied for FDA approval, and much of what is reported about it comes from clinical experience and patient accounts rather than from controlled trials. This article is for education only. It is not medical advice and is not an offer of treatment. Talk with a licensed provider before making any decision about your health.
What microdosing means
In this context, microdosing does not mean a different medication. It means taking a lower dose of the same GLP-1 medications used in standard treatment, with the dose chosen by a provider for an individual patient. The term is informal and has no single medical definition. It is also not a claim that a lower dose works better than a standard dose.
What the trials show about dose
The large trials that led to FDA approval of these medications for weight management tested the full approved doses. In the STEP 1 trial, adults who took weekly semaglutide lost an average of 14.9 percent of body weight over 68 weeks, compared with 2.4 percent for placebo.
The clearest published evidence about lower doses comes from an earlier dose-ranging trial. In that phase 2 trial, adults with obesity were assigned to one of several daily doses of semaglutide or to placebo for 52 weeks. Every semaglutide dose produced more weight loss than placebo. However, weight loss was smaller at the lower doses and larger at the higher doses. The most common side effects were gastrointestinal symptoms, primarily nausea, and they were related to dose.
Two conclusions follow from that trial. Lower doses can still reduce weight compared with no treatment. People who take a lower dose should also expect less weight loss, on average, than people who take a full dose.
What the evidence does not show
We are not aware of a large randomized trial that has tested a deliberately low long-term dose as a weight-management strategy and compared it with standard treatment. Claims that microdosing produces specific percentages of weight loss, specific reductions in nausea or specific completion rates are not supported by published controlled data. Those claims should be treated with caution until such trials exist.
Side effects and tolerability
According to the prescribing information, nausea, vomiting and diarrhea were the most common adverse reactions that led trial participants to stop semaglutide. In STEP 1, nausea and diarrhea were the most common adverse events. They were typically mild to moderate and eased over time. Gastrointestinal events led 4.5 percent of participants taking semaglutide to stop treatment, compared with 0.8 percent of those taking placebo. Because these side effects are related to dose, it is reasonable to expect that a lower dose may be easier to tolerate for some people. That expectation comes from the dose-ranging data. It has not been confirmed by a trial designed to test it.
A lower dose does not remove the other risks of these medications. The boxed warning about thyroid C-cell tumors, the contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN2, and the warnings about pancreatitis, gallbladder disease and dehydration apply at every dose.
Who might discuss this approach with a provider
A conversation about a lower-dose approach may make sense for an adult who has had trouble tolerating a GLP-1 medication in the past, or who wants a more gradual start and accepts that results may be more modest. It is less likely to suit someone whose provider has advised that substantial weight loss is needed for medical reasons. In every case, the dose is a clinical decision that a provider makes for an individual patient, not a choice that a patient makes alone.
Where Truthe fits
The Truthe Rx MICRODOSING program offers a lower-dose GLP-1 approach to adults. The trials described in this article studied branded products. Ask your provider how the medication in this program is prepared. Truthe does not prescribe, and an independent licensed provider decides whether a prescription is appropriate for you and at what dose.
Disclaimer: This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting or changing any medication.
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID 33567185. doi.org/10.1056/NEJMoa2032183
- O'Neil PM, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-649. PMID 30122305. doi.org/10.1016/S0140-6736(18)31773-2
- U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information: boxed warning, contraindications, and warnings and precautions. accessdata.fda.gov
Ready to Start?
Explore personalized treatment plans designed around your goals. Every plan is supported by licensed providers and premium compounding pharmacies.
